Hypertension is the metabolic syndrome component most strongly associated with microvascular complications and coronary artery calcification in Type 1 diabetes

被引:1
作者
Rodrigues, T. C. [1 ]
Canani, L. H.
Schvartzman, P. [2 ]
Gross, J. L.
机构
[1] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Serv Endocrinol, Div Endocrine, BR-90035003 Porto Alegre, RS, Brazil
[2] Hosp Moinhos Vento, Div Radiol, Porto Alegre, RS, Brazil
关键词
Metabolic syndrome; hypertension; microvascular complications; coronary arterial calcification; type; 1; diabetes; GLUCOSE DISPOSAL RATE; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; SUBCLINICAL ATHEROSCLEROSIS; PITTSBURGH EPIDEMIOLOGY; INCREASED PREVALENCE; BLOOD-PRESSURE; PROGRESSION; NEPHROPATHY; MORTALITY;
D O I
10.1007/BF03347077
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To evaluate the association of metabolic syndrome (MetS) and its individual components with microvascular complications and coronary artery calcification (CAC) in patients with Type 1 diabetes. Material/Subjects and methods: Cross-sectional study included 261 patients with Type 1 diabetes. Patients were assessed regarding the presence of MetS according to National Cholesterol Education Program (NCEP) criteria. CAC score was measured in a subset of 100 patients without known cardiovascular disease. Results: The prevalence of MetS was 13.4% according to the NCEP criteria. Microvascular complications and CAC were more frequent in patients with MetS. In a multiple logistic regression analysis, MetS remained associated with nephropathy [OR: 6.33 (95% CI 2.54-15.77), p<0.0011, but not with retinopathy and CAC. Among the MetS components, hypertension was associated with presence of retinopathy [OR: 4.04 (95% CI 1.65-9.90), p=0.002], nephropathy [OR: 5.92 (95% CI 2.42-14.4), p<0.001] and CAC [OR: 2.97 (95% CI 1.06-8.30), p=0.03]. Conclusions: Hypertension was the only MetS component associated with retinopathy, nephropathy and the presence of CAC. Hypertension was better associated with CAC than MetS itself. (J. Endocrinol. Invest 34: e58-e63, 2011) (C)2011, Editrice Kurtis
引用
收藏
页码:E58 / E63
页数:6
相关论文
共 32 条
  • [1] The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions
    Athyros, VG
    Ganotakis, ES
    Elisaf, M
    Mikhailidis, DP
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (08) : 1157 - 1159
  • [2] The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes - Results from Metascreen, a multicenter diabetes clinic-based survey
    Bonadonna, Riccarcdo C.
    Cucinotta, Domenico
    Fedele, Domenico
    Riccardi, Gabriele
    Tiengo, Antonio
    [J]. DIABETES CARE, 2006, 29 (12) : 2701 - 2707
  • [3] The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study
    Bonora, E
    Targher, G
    Formentini, G
    Calcaterra, F
    Lombardi, S
    Marini, F
    Zenari, L
    Saggiani, F
    Poli, M
    Perbellini, S
    Raffaelli, A
    Gemma, L
    Santi, L
    Bonadonna, RC
    Muggeo, M
    [J]. DIABETIC MEDICINE, 2004, 21 (01) : 52 - 58
  • [4] Assessment of coronary artery disease by cardiac computed tomography - A scientific statement from the American Heart Association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology
    Budoff, Matthew J.
    Achenbach, Stephan
    Blumenthal, Roger S.
    Carr, J. Jeffrey
    Goldin, Jonathan G.
    Greenland, Philip
    Guerci, Alan D.
    Lima, Joao A. C.
    Rader, Daniel J.
    Rubin, Geoffrey D.
    Shaw, Leslee J.
    Wiegers, Susan E.
    [J]. CIRCULATION, 2006, 114 (16) : 1761 - 1791
  • [5] Estimated Glucose Disposal Rate in Assessment of the Metabolic Syndrome and Microvascular Complications in Patients with Type 1 Diabetes
    Chillaron, Juan J.
    Goday, Alberto
    Flores-Le-Roux, Juana A.
    Benaiges, David
    Carrera, Maria J.
    Puig, Jaume
    Cano-Perez, Juan F.
    Pedro-Botet, Juan
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (09) : 3530 - 3534
  • [6] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [7] Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes
    Costa, LA
    Canani, LH
    Lisbôa, HRK
    Tres, GS
    Gross, JL
    [J]. DIABETIC MEDICINE, 2004, 21 (03) : 252 - 255
  • [8] Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: The Fremantle Diabetes Study
    Davis, Timothy M. E.
    Bruce, David G.
    Davis, Wendy A.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 78 (03) : 412 - 417
  • [9] Dyslipidemias in patients who have chronic kidney disease
    Farbakhsh, K
    Kasiske, BL
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2005, 89 (03) : 689 - +
  • [10] Are predictors of coronary heart disease and lower-extremity arterial disease in type I diabetes the same? A prospective study
    Forrest, KYZ
    Becker, DJ
    Kuller, LH
    Wolfson, SK
    Orchard, TJ
    [J]. ATHEROSCLEROSIS, 2000, 148 (01) : 159 - 169